Navigation Links
McCulley/Cuppan Consultants Contribute Chapter to the Newly Published Book, Rhetoric of Healthcare: Essays Toward a New Disciplinary Inquiry
Date:9/13/2008

lley/Cuppan consulting to the drug industry. Collectively they have worked with over 50 pharmaceutical companies to assess, coordinate or improve the communication quality of literally hundreds of clinical research reports. http://www.mcculley-cuppan.com [McCulley/Cuppan] provides a full range of consulting, training, and writing support to the pharmaceutical R&D industry. The consulting practice is designed to help teams and companies plan and articulate document development strategies, identify issues that documents must address, and find ways to bring team intelligence to the final written products.

The book is published by Hampton Press and further details can be found on their http://www.hamptonpress.com/Merchant2/merchant.mvc?Screen=PROD&Product_Code=1-57273-790-5&Category_Code=Q308 [web site.]

###

Read the full story at http://www.prweb.com/releases/2008/09/prweb1320564.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Health Care Cost Increases to Continue at Double Digit Rates, According to Buck Consultants Survey
2. Hollander Consultants Celebrates 25 Years as an Industry Leader in Successful Medical Practice Management Consulting
3. Employee Involvement Is Key to Long-Term Pharmacy Cost Control, Finds Buck Consultants Survey
4. Senior Healthcare Consultants and Subsidiary Companies Announce Election of Officers & Distribution Managers
5. Buck Consultants Reports Wellness Programs Are Truly Global; Objectives Vary by Region
6. Healthcare Veteran Richard Findlay Joins Diamond Management & Technology Consultants as Partner
7. Scripps Translational Science Institute Contributes to Discovery of Predisposition Gene for Childhood Cancer
8. Service and Hardware Revenues Will Contribute $1.8 Billion to the U.S. Eldercare Industry by 2013
9. Preparing To Send Your Children Off To School? Healthy Breakfast, Lunch and Snack Ideas From Cabot(R) Can Contribute to a Better, More Productive School Year
10. Preterm Birth Contributes to Growing Number of Infant Deaths
11. Preterm birth contributes to growing number of infant deaths
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Heska Announces Extension of Credit Agreement With Wells Fargo 2Heska Announces Extension of Credit Agreement With Wells Fargo 3Anesiva Completes Sale of its Zingo(TM) Assets to Powder Pharmaceuticals and Lee's Pharmaceuticals 2St. Luke's Hospital Acquires Pioneering Technology From BrainLAB 2St. Luke's Hospital Acquires Pioneering Technology From BrainLAB 3Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 1Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 2Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 3Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 4Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 5Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 6Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 7Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 8Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 9Golden Meditech Announces HK 24217 Million Private Equity Financing for Hospital Subsidiary 14309 1Golden Meditech Announces HK 24217 Million Private Equity Financing for Hospital Subsidiary 14309 2Method to Identify Female Athletes at a High Risk for Knee Injury Discovered 58628 1Method to Identify Female Athletes at a High Risk for Knee Injury Discovered 58628 2